Vanguard Group
AVTX icon

Vanguard Group’s Avalo Therapeutics AVTX Stock Holding History

Vanguard Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$14.6M Buy
804,084
+111,447
+16% +$1.88M ﹤0.01% 2767
2025
Q3 		$8.8M Buy
692,637
+525,696
+315% +$4.52M ﹤0.01% 3044
2025
Q2 		$833K Hold
166,941
– – ﹤0.01% 3787
2025
Q1 		$1.34M Buy
166,941
+1,140
+0.7% +$8.64K ﹤0.01% 3623
2024
Q4 		$1.23M Buy
165,801
+155,433
+1,499% +$1.66M ﹤0.01% 3697
2024
Q3 		$98.1K Hold
10,368
– – ﹤0.01% 4200
2024
Q2 		$129K Buy
+10,368
New +$134K ﹤0.01% 4206
2023
Q4 		– Sell
-383
Closed -$11.1K – 4499
2023
Q3 		$11.1K Sell
383
-542
-59% -$24.2K ﹤0.01% 4520
2023
Q2 		$78.9K Hold
925
– – ﹤0.01% 4409
2023
Q1 		$389K Hold
925
– – ﹤0.01% 4189
2022
Q4 		$1.12M Hold
925
– – ﹤0.01% 3871
2022
Q3 		$736K Sell
925
-141
-13% -$153K ﹤0.01% 4094
2022
Q2 		$1.53M Sell
1,066
-109
-9% -$146K ﹤0.01% 3927
2022
Q1 		$2.45M Buy
1,175
+2
+0.2% +$5.02K ﹤0.01% 3874
2021
Q4 		$5.74M Buy
1,173
+11
+0.9% +$66K ﹤0.01% 3526
2021
Q3 		$7.3M Buy
1,162
+51
+5% +$413K ﹤0.01% 3424
2021
Q2 		$10.5M Buy
1,111
+177
+19% +$1.48M ﹤0.01% 3173
2021
Q1 		$8.12M Buy
934
+149
+19% +$1.41M ﹤0.01% 3269
2020
Q4 		$5.97M Buy
785
+32
+4% +$222K ﹤0.01% 3280
2020
Q3 		$4.93M Buy
753
+249
+49% +$1.87M ﹤0.01% 3152
2020
Q2 		$3.78M Buy
504
+217
+76% +$1.58M ﹤0.01% 3217
2020
Q1 		$2.05M Buy
287
+34
+13% +$360K ﹤0.01% 3310
2019
Q4 		$3.92M Sell
253
-1
-0.4% -$10.5K ﹤0.01% 3250
2019
Q3 		$2.4M Buy
254
+19
+8% +$212K ﹤0.01% 3389
2019
Q2 		$3.69M Buy
235
+85
+57% +$1.29M ﹤0.01% 3270
2019
Q1 		$2.53M Buy
150
+47
+46% +$703K ﹤0.01% 3372
2018
Q4 		$955K Buy
103
+72
+232% +$802K ﹤0.01% 3574
2018
Q3 		$411K Buy
31
+3
+11% +$39.3K ﹤0.01% 3881
2018
Q2 		$346K Sell
28
-27
-49% -$322K ﹤0.01% 3893
2018
Q1 		$678K Buy
55
+35
+175% +$394K ﹤0.01% 3729
2017
Q4 		$182K Buy
20
+1
+5% +$4.31K ﹤0.01% 3947
2017
Q3 		$48K Sell
19
-1
-5% -$2.14K ﹤0.01% 4031
2017
Q2 		$34K Buy
20
+1
+5% +$1.63K ﹤0.01% 4044
2017
Q1 		$37K Sell
19
-5
-21% -$11.9K ﹤0.01% 4041
2016
Q4 		$62K Buy
+24
New +$219K ﹤0.01% 4010

Other funds holding AVTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group's AVTX Position: Q4 2025 in Review

Vanguard Group increased its Avalo Therapeutics (AVTX) stake by 16% in Q4 2025, buying an estimated $1.88M and bringing the position to 804,084 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2767.

Vanguard Group first reported a position in AVTX in Q4 2016 and has held it in 35 quarters since. 84 funds tracked by Wall St. Rank hold AVTX as of Q4 2025.

  • Vanguard Group held 804,084 shares of Avalo Therapeutics worth $14.6M as of Q4 2025.
  • Vanguard Group bought 111,447 Avalo Therapeutics shares in Q4 2025, an estimated $1.88M.
  • Avalo Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2767 holding.
  • Vanguard Group first reported a position in Avalo Therapeutics in Q4 2016 and has held it in 35 quarters since.
  • 84 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.